What are the possible reasons why there is no improvement after taking Avonib for three years?

Ivosidenib (Ivosidenib) is a small molecule inhibitor that specifically targets isocitrate dehydrogenase 1 (IDH1) mutations. It is widely used in patients with acute myeloid leukemia (AML) and cholangiocarcinoma who carry IDH1 mutations. However, in clinical practice, some patients do not see significant improvement even after taking medication for many years. Multiple complex factors may be involved behind this phenomenon.

First of all, drug resistance is one of the main reasons. As the treatment time increases, tumor cells may escape IDH1 inhibition by activating alternative signaling pathways (such asRAS/MAPK, PI3K/AKT) or developing new gene mutations, thereby developing secondary resistance to ivonib. In addition, some patients may have low dependence on the IDH1 pathway. Although the drug targets the mutated gene, it cannot significantly inhibit tumor progression in the actual mechanism of action, manifesting as poor clinical response rate or only maintaining disease stability without substantial improvement.

Another possible factor isThe heterogeneity of IDH1 mutations. In some patients, mutations only exist in some tumor clones. As treatment progresses, mutated clones may be exhausted or replaced by other non-mutated clones, causing the target of ivonib to be gradually lost. In addition, differences in drug absorption, metabolism, comorbidity with other underlying diseases, or concomitant drugs that interfere with drug efficacy may also affect treatment results. In some cases, differentiation syndrome may be misdiagnosed or improperly treated, which may affect long-term efficacy.

In general, if there is no improvement after taking ivonib for three years, attention should be paid. It is recommended to reviewIDH1 mutation status, conduct resistance mechanism analysis, and if necessary, combine chemotherapy, hypomethylating drugs, and even consider hematopoietic stem cell transplantation to optimize treatment strategies.

Reference: https://www.tibsovo.com/